Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab and Olaparib in Recurrent or Metastatic Cervical Cancer
NCT04641728Phase 2Unknown
- Sponsor
- Saitama Medical University International Medical Center
- Start
- Jan 2021
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of olaparib in Cervical Cancer (CC), sponsored by Saitama Medical University International Medical Center. Status: unknown.
02
Drugs
olaparib
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT04641728.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04641728.